Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186043 · ClinicalTrials.gov registry record · Phase 4
Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT00186043: Completed Phase 4 study, sponsored by Stanford University.
NCT00186043 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186043, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
1. The primary objective of this study is to examine the efficacy of quetiapine (Seroquel) in treatment of dysphoric hypomania in patients with Bipolar II disorder. 2. To evaluate the utility of Seroquel add-on treatment to decrease mixed depressive and hypomanic symptoms.
Interventions
- DRUG Placebo
- DRUG Quetiapine/Seroquel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186043
The ClinicalTrials.gov registry entry for NCT00186043 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00186043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186043 about?
NCT00186043 is a clinical study titled "Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II". 1. The primary objective of this study is to examine the efficacy of quetiapine (Seroquel) in treatment of dysphoric hypomania in patients with Bipolar II disorder. 2. To evaluate the utility of Seroquel add-on treatment to decrease mixed depressive and hypomanic symptoms.
What is the current status of trial NCT00186043?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2008-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00186043?
The interventions under investigation include: Placebo (DRUG), Quetiapine/Seroquel (DRUG).
Who is sponsoring clinical trial NCT00186043?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.